<DOC>
	<DOC>NCT01968616</DOC>
	<brief_summary>In retinal vein occlusion, predictive factors for visual outcome after ranibizumab treatment have not been evaluated comprehensively. Therefore, we have planned to analyze predictors for visual outcome from a viewpoint of electrophysiology and biomarkers besides morphological features by SD-OCT.</brief_summary>
	<brief_title>Ranibizumab Treatment for Retinal Vein Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Signed informed consent form Male or female of aged 18 years or older Macula edema secondary to BRVO/CRVO Decrease of VA due to macular edema Prior episode of RVO Previous treatment with antiVEGF drugs or corticosteroid or grid laser photocoagulation (study eye) Ocular disorders in the study eye that may confound interpretation of study results History of vitrectomy surgery, submacular surgery, or other surgical intervention for RVO The pregnant or lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>